Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Silo Pharma, Inc. (UCUT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/29/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Fifth Amendment To Commercial Evaluation and License Agreement This Fifth Amendment to Commercial Evaluation and License Agreement is effective as of the date of the last signature on the signature page between the UNIVERSITY OF MARYLAND, BALTIMORE , a public university that is part of the University System of Maryland , and SILO PHARMA, INC., a Florida corporation . BACKGROUND"
05/26/2023 4 Ryweck Daniel E. (CFO) has filed a Form 4 on Silo Pharma, Inc.
Txns: Bought 1,000 shares @ $2.1264, valued at $2.1k
05/18/2023 4 Weisblum Eric (CEO and President) has filed a Form 4 on Silo Pharma, Inc.
Txns: Bought 2,500 shares @ $2.06, valued at $5.2k
Bought 500 shares @ $2.107, valued at $1.1k
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia SPU-26 Pain Management Using Ketamine Composition"
03/24/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Reda Joseph reports a 9.9% stake in Silo Pharma, Inc.
02/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
01/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
01/20/2023 8-K Other Events  Interactive Data
12/20/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/01/2022 8-K Quarterly results
11/15/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/18/2022 8-K Quarterly results
10/04/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
10/04/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
09/30/2022 8-K Quarterly results
09/28/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
09/27/2022 CERT Form CERT - Certification by an exchange approving securities for listing:
09/27/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/26/2022 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
09/20/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
09/15/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF SILO PHARMA, INC.",
"Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq"
08/01/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/22/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/21/2022 4 Weisblum Eric (CEO, CFO and President) has filed a Form 4 on Silo Pharma, Inc.
Txns: Bought 13,080 shares @ $0.1147, valued at $1.5k
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
03/28/2022 10-K Annual Report for the period ended December 31, 2021
03/11/2022 8-K Quarterly results
03/07/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy